Inability to detect an inhibitor of thyroxine-serum protein binding in sera from patients with nonthyroid illness. 1991

C M Mendel, and C W Laughton, and F A McMahon, and R R Cavalieri
Cardiovascular Research Institute, University of California, San Francisco 94143-0130.

Sera from 111 patients hospitalized on acute-care wards (including 32 in the intensive care unit) were examined for the possible presence of inhibitors of thyroxine (T4)-serum protein binding in an assay employing equilibrium dialysis. In 38 of these sera, the unbound (free) T4 fraction was 50% or more higher than the free T4 fraction in a pool of normal sera. From the free T4 fraction in each of the 111 serum samples and the free T4 fraction in the pool of normal sera, the predicted free T4 fractions in mixtures (1:1) of each of these sera with the normal pool were calculated (assuming the absence of binding inhibitors) from the appropriate mass action equations. It was reasoned that a free T4 fraction in any mixture that exceeded this predicted value would indicate the possible presence of a binding inhibitor. (The normal pool was selected for having a low serum triglyceride concentration, to minimize in vitro generation of free fatty acids.) However, for the 111 serum samples studied, the free T4 fraction in the mixture exceeded the upper 95% confidence limit of this predicted value in only one case, and then just barely. Thus, evidence for an inhibitor of T4-serum protein binding in sera from patients with nonthyroid illness could not be found. Twenty-eight of the serum samples were also examined in a similar assay that employed ultrafiltration of undiluted serum instead of equilibrium dialysis. Evidence for an inhibitor of T4-serum protein binding similarly could not be found. Because part of the reason for postulating the existence of such a binding inhibitor has been the performance of the triiodothyronine (T3) resin uptake test in patients with nonthyroid illness, an alternative explanation for this phenomenon was sought. When thyroid hormone-binding globulin (TBG) was desialylated by treatment with neuraminidase, its avidity for T4 was markedly decreased, but its avidity for T3 was unchanged. Thus, if desialylated TBG circulates in patients with nonthyroid illness as previously reported, it could explain not only the low serum T4 concentrations despite near normal immunoreactive TBG concentrations, but also the poor performance of the T3 resin uptake test (where T4 binding capacity is overestimated) in these patients.

UI MeSH Term Description Entries
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D003956 Dialysis A process of selective diffusion through a membrane. It is usually used to separate low-molecular-weight solutes which diffuse through the membrane from the colloidal and high-molecular-weight solutes which do not. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013959 Thyroid Diseases Pathological processes involving the THYROID GLAND. Disease, Thyroid,Diseases, Thyroid,Thyroid Disease
D013974 Thyroxine The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism. L-Thyroxine,Levothyroxine,T4 Thyroid Hormone,3,5,3',5'-Tetraiodothyronine,Berlthyrox,Dexnon,Eferox,Eltroxin,Eltroxine,Euthyrox,Eutirox,L-3,5,3',5'-Tetraiodothyronine,L-Thyrox,L-Thyroxin Henning,L-Thyroxin beta,L-Thyroxine Roche,Levo-T,Levothroid,Levothyroid,Levothyroxin Deladande,Levothyroxin Delalande,Levothyroxine Sodium,Levoxine,Levoxyl,Lévothyrox,Novothyral,Novothyrox,O-(4-Hydroxy-3,5-diiodophenyl) 3,5-diiodo-L-tyrosine,O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine,Oroxine,Sodium Levothyroxine,Synthroid,Synthrox,Thevier,Thyrax,Thyroxin,Tiroidine,Tiroxina Leo,Unithroid,L Thyrox,L Thyroxin Henning,L Thyroxin beta,L Thyroxine,L Thyroxine Roche,Levo T,Thyroid Hormone, T4
D013975 Thyroxine-Binding Proteins Blood proteins that bind to THYROID HORMONES such as THYROXINE and transport them throughout the circulatory system. Thyroxine Transport Protein,Thyroxine-Binding Protein,Thyroxine Binding Protein,Thyroxine Binding Proteins

Related Publications

C M Mendel, and C W Laughton, and F A McMahon, and R R Cavalieri
July 1979, The Journal of clinical endocrinology and metabolism,
C M Mendel, and C W Laughton, and F A McMahon, and R R Cavalieri
June 1984, The Journal of clinical endocrinology and metabolism,
C M Mendel, and C W Laughton, and F A McMahon, and R R Cavalieri
April 1981, Metabolism: clinical and experimental,
C M Mendel, and C W Laughton, and F A McMahon, and R R Cavalieri
February 1967, The Journal of clinical endocrinology and metabolism,
C M Mendel, and C W Laughton, and F A McMahon, and R R Cavalieri
November 1987, The Journal of clinical endocrinology and metabolism,
C M Mendel, and C W Laughton, and F A McMahon, and R R Cavalieri
December 1983, The Journal of clinical endocrinology and metabolism,
C M Mendel, and C W Laughton, and F A McMahon, and R R Cavalieri
May 1985, The Journal of clinical endocrinology and metabolism,
C M Mendel, and C W Laughton, and F A McMahon, and R R Cavalieri
November 2016, Toxicon : official journal of the International Society on Toxinology,
Copied contents to your clipboard!